Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 31
Back to Home
Tirzepatide
Max Weight Loss20.9%
Studies12
Participants8,750
StatusAvailable

Tirzepatide

Dual GIP and GLP-1 Receptor Agonist

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Available as FDA-approved Mounjaro® for Type 2 diabetes and Zepbound® for weight management and obstructive sleep apnea. It provides superior weight loss and glycemic control compared to single-pathway medications through its unique dual mechanism of action.

Complete Research Database

Dual Receptor Mechanism (GIP/GLP-1)

GLP-1 Receptor Pathway

  • •Increases insulin secretion (glucose-dependent)
  • •Suppresses glucagon release
  • •Slows gastric emptying
  • •Enhances satiety in hypothalamus
  • •Preserves beta-cell function

GIP Receptor Pathway

  • •Enhances insulin secretion (stronger than GLP-1)
  • •Promotes fat oxidation
  • •Improves insulin sensitivity in muscle
  • •Reduces hepatic glucose production
  • •Modulates adipose tissue metabolism

Why Dual Agonism is Superior

Tirzepatide is a dual receptor agonist that activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual mechanism provides superior efficacy compared to single-pathway approaches. GIP receptor activation enhances insulin secretion, improves glucose tolerance, and promotes fat oxidation. GLP-1 receptor activation reduces appetite, slows gastric emptying, improves glucose-dependent insulin secretion, and reduces glucagon release.

Pharmacokinetic Profile

~5 days
Half-life
8-72 hours
Tmax
80%
Bioavailability
99%
Protein binding
Proteolytic cleavage
Metabolism
Renal (primary)
Elimination

Top 10 High-Quality Research Articles

Tirzepatide Once Weekly for the Treatment of Obesity

Read
New England Journal of Medicine (2022)
N = 2,539
High Impact
20.9% weight reduction with 15mg dose over 72 weeks
DOI: 10.1056/NEJMoa2206038

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

Read
New England Journal of Medicine (2021)
N = 1,879
High Impact
Superior glycemic control: HbA1c reduction 2.24% vs 1.86%
DOI: 10.1056/NEJMoa2107519

Effect of Continued Weekly Subcutaneous Tirzepatide vs Placebo

Read
JAMA (2023)
N = 783
High Impact
Continued therapy maintained 25.3% weight loss; withdrawal led to regain
DOI: 10.1001/jama.2023.24945

Tirzepatide and Cardiovascular Outcomes in Type 2 Diabetes

Read
New England Journal of Medicine (2024)
N = 12,847
High Impact
8% reduction in major adverse cardiovascular events
DOI: 10.1056/NEJMoa2410027

Safety and Tolerability of Tirzepatide: Integrated Analysis

Read
Diabetes Care (2023)
N = 8,918
Medium Impact
5.3% discontinuation rate, primarily GI-related
DOI: 10.2337/dc22-2395
Search PubMed for 'tirzepatide clinical trials' for the most comprehensive database of peer-reviewed research on this dual GIP/GLP-1 receptor agonist.

Medical Disclaimer

Tirzepatide is FDA-approved as Mounjaro® for Type 2 diabetes and Zepbound® for chronic weight management. This information is for educational purposes and should not replace consultation with healthcare providers. Individual results may vary. Prescribing information and medical supervision are required for all therapeutic uses.